Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic retinopathy being investigated by Eli Lilly and Company. It is an orally active small-molecule inhibitor selective for protein kinase C beta isoforms, originally developed under the research code LY333531, and formulated in clinical work as the mesylate salt. Mechanistically, ruboxistaurin modulates signaling pathways implicated in hyperglycemia-induced retinal vascular dysfunction, aiming to reduce retinal capillary leakage and microaneurysm progression; preclinical and clinical pharmacology data describe dose-dependent PKC beta inhibition, systemic exposure following oral dosing, and metabolism consistent with hepatic biotransformation monitored by LC-MS methods.
Parent: Ruboxistaurin
Typical analytical control for ruboxistaurin API follows ICH impurity guidance with conservative acceptance criteria used in development and regulatory filings: individual identified related compounds are commonly limited to 0.5 percent weight by weight or less, any single unspecified impurity is generally controlled to 0.10 percent w/w or less, and total impurities are routinely specified not to exceed 1.0 percent w/w; degradation products are characterized by LC-MS and HPLC with diode array detection and qualified when above identification thresholds, residual solvents are controlled per ICH Q3C with limits expressed in ppm, and elemental impurities are managed per ICH Q3D.
Ruboxistaurin has been investigated as a therapy to slow or prevent progression of diabetic retinopathy by inhibiting protein kinase C beta to reduce retinal vascular leakage and microvascular damage; its use to date has been limited to clinical trials.
The proposed brand name is Arxxant and the compound was developed by Eli Lilly and Company under the code LY333531.
